Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability (2019 - 2025)
Supernus Pharmaceuticals (SUPN) has disclosed Non-Current Deferred Tax Liability for 8 consecutive years, with $981000.0 as the latest value for Q1 2025.
- Quarterly Non-Current Deferred Tax Liability fell 94.97% to $981000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $981000.0 through Mar 2025, down 94.97% year-over-year, with the annual reading at $137.7 million for FY2024, 451.6% up from the prior year.
- Non-Current Deferred Tax Liability for Q1 2025 was $981000.0 at Supernus Pharmaceuticals, down from $137.7 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $137.7 million in Q4 2024, with the low at $981000.0 in Q1 2025.
- Average Non-Current Deferred Tax Liability over 5 years is $43.9 million, with a median of $35.2 million recorded in 2023.
- The sharpest move saw Non-Current Deferred Tax Liability surged 451.6% in 2024, then crashed 94.97% in 2025.
- Over 5 years, Non-Current Deferred Tax Liability stood at $85.4 million in 2021, then tumbled by 41.64% to $49.8 million in 2022, then crashed by 49.88% to $25.0 million in 2023, then soared by 451.6% to $137.7 million in 2024, then plummeted by 99.29% to $981000.0 in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $981000.0, $137.7 million, and $7.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.